Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1817-1822

  Campo Esquisabel, A B ^a,b   Rodriguez M C ^b,c   Campo Sosa, A O ^b   Rodriguez C ^b   Martinez Martinez L ^b  

^a HOSPITAL SIERRALLANA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c University of Cantabria   (Spain)

Author keywords

Cefepime; Efflux pumps; PSE 1; Pseudomonas aeruginosa; Resistance

Indexed keywords

AMINO ACID; CEFEPIME; CEFTAZIDIME;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; GENE EXPRESSION; GENE MUTATION; MEXB BACTERIAL GENE; MEXD BACTERIAL GENE; MEXR GENE; MEXZ BACTERIAL GENE; MINIMUM INHIBITORY CONCENTRATION; NALC GENE; NALD GENE; NFXB GENE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

PSEUDOMONAS AERUGINOSA;

EID: 81255185583     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03530.x     Document Type: Article

References (30)

1. Vila J, Marco F. [Interpretive reading of the non-fermenting gram-negative bacilli antibiogram.]. Enferm Infecc Microbiol Clin 2010; 28: 726-736.
2. Hocquet D, Nordmann P, El Garch F et al. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1347-1351.
3. Aubert D, Poire L, Chevalier J et al. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 1615-1620.
4. Aubert D, Poirel L, Ali AB, Goldstein FW, Nordmann P. OXA-35 is an OXA-10-related beta-lactamase from Pseudomonas aeruginosa. J Antimicrob Chemother 2001; 48: 717-721.
5. Somvadee L. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infect Drug Resist 2008; 1: 51-55.
6. Baum EZ, Crespo-Carbone SM, Morrow BJ et al. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 2785-2790.
7. Peña C, Suarez C, Tubau F et al. Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 ß-lactamase. J Clin Microbiol 2009; 47: 2381-2387.
8. Nikaido H, Zgurskaya HI. Antibiotic efflux mechanisms. Curr Opin Infect Dis 1999; 12: 529-536.
9. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsijimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYOprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
10. Hocquet D, Berthelot P, Roussel-Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007; 51: 3531-3536.
11. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 2008; 52: 2455-2462.
12. Sader HS, Fritsche TR, Jones RN. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J Clin Microbiol 2006; 44: 1101-1104.
13. Juretschko S, Labombardi VJ, Lerner SA, Schreckenberger PC; and the Pseudomonas AST Study Group. Accuracies of β-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems. J Clin Microbiol 2007; 45: 1339-1342.
14. Joyanes P, del Carmen Conejo M, Martínez-Martínez L, Perea EJ. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J Clin Microbiol 2001; 39: 3247-3253.
15. Biedenbach DJ, Marshall SA, Jones RN. Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. Diagn Microbiol Infect Dis 1999; 33: 305-307.
16. Jones RN, Biedenbach DJ, Marshall SA, Pfaller MA, Doern GV. Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. Diagn Microbiol Infect Dis 1998; 32: 107-110.
17. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard- Eighth Edition. M07-A8. CLSI, 2009. Wayne, Pa.
18. Vila J, Marcos MA, Jiménez de Anta MT. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. J Med Microbiol 1996; 44: 482-489.
19. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restricition patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
20. Lee S, Park YJ, Kim M et al. Prevalence of Ambler class A and D b-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56: 122-127.
21. Gutiérrez O, Juan C, Cercenado E et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother 2007; 51: 4329-4335.
22. Ziha-Zarifi I, Llanes C, Köhler T, Pechère J-C, Plesiat P. In vivo emergence of multidrug-resistance mutants of Pseudomonas aeruginosa overexpressing the active afflux systems MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
23. Pai H, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-484.
24. Kiser TH, Obritsch MD, Jung R, MacLaren R, Fish DN. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy 2010; 30: 632-638.
25. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plesiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48: 1797-1802.
26. Srikumar R, Paul CJ, Poole K. Influence of mutation in the mexR repressor gene on expression of the MexAB-OprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 2000; 182: 1410-1414.
27. Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003; 47: 3202-3207.
28. Vogne C, Aires JR, Bailly C, Hocquet D, Plésiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 1676-1680.
29. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz F-J. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 409-413.
30. Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother 2009; 53: 1552-1560.